People in Europe and the US rarely pay for prescription drugs out of their own pockets. In Europe, their national health services almost always pick up the tab – even if some people have to contribute by way of a prescription charge. In the US, the health insurer normally foots the bill. But things have […]
You have probably already seen the news: not one but two major European life science funds have closed in the last week – collectively raising a massive €1.15 billion! Last Friday (November 14), leading European life sciences venture capital firm Medicxi announced it had closed its €500 million Medicxi V fund. And on Monday, (November […]
You’d expect us here at Optimum Strategic Communications to be excited about Nobel Prize season – particularly the gongs for the two categories of Physiology or Medicine and Chemistry. And we have been. But it’s this year’s Nobel Prize for Economic Sciences that really caught our eye, because it has major implications for the life […]
The big buzz around AI in healthcare is the potential it holds to identify and even create new drugs. “AI drug discovery” is the great new hope. And – despite critics awkwardly pointing out that no AI-generated drugs have yet been approved by any regulator, and vanishing few appear to be close to that finishing […]
Challenges to pharma charging premium prices for branded drugs are not new. Think of President Biden’s attempts to drive down prices with the Inflation Reduction Act. Or the UK’s strategy of capping the price the NHS pays for branded medicines with its VPAG rebate scheme. But President Trump’s “most favoured nation” policy – which attempts […]
